A polipoprotein (apo) CIII is a small protein that resides in multiple copies on the surface of very-low-density lipoprotein (VLDL) and, to a lesser extent, low-density lipoprotein (LDL). It has been reported that apoCIII inhibits clearance from plasma of VLDL and LDL. [1] [2] [3] Thus, apoCIII causes accumulation in plasma of atherogenic remnant lipoproteins and LDL rich in apoCIII, triglycerides, and cholesterol, which are prominent in diabetic and atherogenic dyslipidemia. 4 -7 Plasma levels of apoCIII containing VLDL and LDL predict risk of cardiovascular disease. 4, 8 The association of apoCIII with cardiovascular disease has been commonly attributed to its inhibitory effect on VLDL and LDL clearance, prolonging the plasma residence time of atherogenic remnant lipoproteins. Although this is undoubtedly true in part, we recently reported that apoCIIIrich VLDL does not have a longer residence time than its apoCIII-free counterparts 9 because slow clearance is balanced by rapid lipolytic conversion to LDL, suggesting that the correlation between apoCIII and risk of coronary heart disease in population studies may be attributable in part to the direct involvement of apoCIII in atherogenesis. We recently showed that apoCIII has direct proinflammatory, atherogenic effects on vascular cells. ApoCIII activates monocytes and endothelial cells to enhance their adhesive interactions in atherosclerosis. 10, 11 
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Endothelial dysfunction is regarded as a causal factor in the initiation and development of cardiovascular disease, including hypertension and atherosclerosis. 12, 13 It is characterized by the reduced bioavailability of the signaling molecule nitric oxide (NO), which has potent vasodilatory and antiatherosclerotic properties. 14 Vascular endothelium is a target tissue of insulin, and insulin resistance exists at the level of vascular endothelial cells. 15, 16 Insulin promotes bioavailability of NO by activating the signaling pathway involving the insulin receptor (IR), IR substrate-1 (IRS-1), phosphatidylinositol 3-kinase (PI3K), and Akt, which leads to the activation of endothelial NO synthase (eNOS). 15 Insulin resistance and subsequent hyperinsulinemia also stimulate secretion of a potent vasoconstrictor endothelin-1 (ET-1) through mitogenactivated protein (MAP) kinase independently of PI3K-dependent signaling, which also contributes to endothelial dysfunction. 17 Endothelial dysfunction is often seen in dyslipidemia and the metabolic syndrome, 18 and the apoCIII level is high in these morbid conditions. 6, 7 ApoCIII is produced mainly in the liver, and its promoter has a negative insulin response element, which may account for the link between the impaired insulin action in hepatocytes and high apoCIII level. 19 In the periphery, it is possible that reverse causation may be operative, involving apoCIII and insulin action, because protein kinase C-␤ (PKC␤) inhibits insulin action in endothelial cells 20 and apoCIII activates PKC␤ in the same cells. 11 Thus, we tested the hypothesis that apoCIII itself impairs insulin signaling in endothelial cells, which results in diminished NO production. This hypothesis would add to the mechanisms by which apoCIII contributes to atherosclerosis and link dyslipidemia with vascular endothelial dysfunction.
Methods

Cell Culture and Reagents
Human umbilical vein endothelial cells (HUVECs) were purchased from Clonetics Corp (San Diego, Calif) and cultured as previously described. 11 HUVECs at passage 2 to 3 were used for the assays. Apolipoproteins were purified from human plasma with highperformance liquid chromatography and immunoaffinity column chromatography (Academy Biomedical Co, Inc, Houston, Tex). Endotoxin levels in apolipoproteins, measured with a Limulus amebocyte lysate chromogenic test (Associates of Cape Cod, East Falmouth, Mass), were Ͻ0.03 EU/mL. Free fatty acid (FFA) levels in apolipoproteins determined enzymatically were Ͻ20 nmol/L, which is much lower than reported to inhibit insulin signaling in endothelial cells. 21 Antiapolipoprotein antibodies were purchased from Academy Biomedical Company, Inc. PD98059, wortmannin, and PKC␤-specific inhibitor [3-(1-(3-Imidazol-1-ylpropyl)-1H-indol-3-yl)-4-anilino-1H-pyrrole-2,5-dione] were purchased from Calbiochem (San Diego, Calif). Insulin was purchased from Wako (Tokyo, Japan).
Lipoprotein Preparation
Blood was drawn in tubes containing EDTA from 10 healthy volunteers after 12 hours of fasting. The subjects were not taking cardiovascular medications, antioxidants, or estrogen. VLDL (dϽ1.006) with apoCIII (VLDL CIIIϩ) or without apoCIII (VLDL CIIIϪ) was isolated from plasma as described previously. 10 The protocol of this study complied with the guidelines for the conduct of research involving human subjects by the Committee on Human Research at Tokyo Medical and Dental University. Apolipoprotein levels in VLDL preparations were determined by ELISA as described previously. 4 Triglyceride levels in VLDL preparations were determined enzymatically. Endotoxin levels in VLDL preparations were Ͻ0.03 EU/mL.
Immunoblotting
After being cultured for 24 hours in the serum-deprived medium without albumin, HUVECs were incubated with apoCIII or VLDL CIIIϩ and then stimulated with insulin. Total lysate and the membrane fraction of the cell lysate were prepared as described previously. 11 Lysate was assayed with immunoblotting using antiphospho-Akt antibody, anti-Akt antibody, anti-phospho-PI3K antibody, anti-PI3K antibody, anti-phospho-IRS-1 (Tyr   989   ) 
In Vivo ApoCIII Stimulation
Please see the Materials and Methods section of the online Data Supplement.
Isometric Tension Measurements
Please see supplementary Materials and Methods section.
Statistical Analysis
Results are given as meanϮSD. Data were analyzed with an unpaired t test or 2-way ANOVA, with values of PϽ0.05 considered significant.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
ApoCIII Inhibits Insulin-Stimulated IRS-1 Tyrosine Phosphorylation in HUVECs
On insulin stimulation, IRS-1 is tyrosine phosphorylated by the IR to activate PI3K/Akt in vascular endothelial cells. 17 We found that exposing HUVECs to apoCIII before insulin treatment blocked this established effect of insulin in a concentration-dependent manner at as early as 30 minutes of exposure ( Figure 1A and 1B) . Therefore, subsequent experiments used apoCIII at 100 g/mL for 30 minutes unless otherwise indicated. ApoCIII did not affect the expression of IR␤ or insulin-induced IR␤ phosphorylation in HUVECs, suggesting that apoCIII affects insulin signaling downstream of IR ( Figure 1C ). Anti-apoCIII antibody, but not isotypematched IgG, completely restored insulin-induced IRS-1 tyrosine phosphorylation (supplemental Figure IA) .
ApoCIII Inhibits Insulin-Stimulated PI3K/Akt and eNOS Activation in HUVECs
PI3K and Akt are sequentially activated downstream of IRS-1, which in turn activates effector molecules in endothelial cells such as eNOS. ApoCIII attenuated insulin-induced phosphorylation of PI3K/Akt in a concentration-dependent manner (Figure 2A and 2B) . ApoCIII attenuated insulinstimulated eNOS activation( Figure 2C ) and NO release into the culture media in a concentration-dependent manner (Figure 2D ). Wortmannin, a PI3K inhibitor, abolished insulininduced eNOS activation and NO release into the culture media. ApoCIII did not affect the expression of eNOS in HUVECs.
ApoCIII Activates PKC␤ in HUVECs
Various isoforms of PKC mediate inflammation and other cellular events in atherosclerosis. Activation of PKC in endothelial cells and vascular tissue inhibits insulin-induced activation of eNOS, leading to impaired vasodilation. 20 We recently showed that apoCIII in VLDL activates PKC␣ in monocytes and PKC␤ in vascular endothelial cells, in which selective inhibition of either PKC isoform abolished apoCIIIinduced upregulation of adhesion molecules. 10,11 Moreover, we previously showed that remnant lipoproteins that are rich in apoCIII activate PKC␣ and PKC␤ in human monocytic cells and PKC␣ and PKC␦ in rat aortic smooth muscle cells. 22, 23 We therefore tested the hypothesis that apoCIII inhibits insulin responses in vascular endothelial cells by activating PKC␤. ApoCIII increased membrane-bound PKC␤II ( Figure 3A) , indicating its activation. ApoCIII minimally affected PKC␤I activation. Anti-apoCIII antibody, but not isotype-matched IgG, completely abolished apoCIIIinduced PKC␤II activation (supplemental Figure IB) . A PKC␤-specific inhibitor attenuated the inhibitory effect of apoCIII on eNOS activation and NO release into the culture media ( Figure 3B and 3C ). These results demonstrate the central role of PKC␤II in impaired insulin signaling induced by apoCIII.
ApoCIII Activates MAP Kinase in HUVECs
Insulin also activates the small GTP binding protein Ras, which then initiates a phosphorylation cascade responsible for growth, mitogenesis, and ET-1 production involving the sequential activation of Raf, MEK, and ERK. 17 We examined whether apoCIII affects insulin-induced ERK activation in endothelial cells. ApoCIII induced phosphorylation of ERK and augmented insulin-induced ERK activation ( Figure 4A) . A PKC␤-specific inhibitor partially reversed apoCIII-induced 
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ERK activation ( Figure 4B ). Andreozzi et al 24 reported that endothelial dysfunction is mediated through activation of JNK or ERK. Recent studies reported that ERK and PKC isoforms induce Ser 616 phosphorylation of IRS-1. 25 It is known that serine phosphorylation of IRS-1 inhibits its ability to be tyrosine phosphorylated by IR and to bind and activate PI3K. We tested the possibility that impaired insulinstimulated IRS-1 function is associated with increased serine phosphorylation induced by PKC␤ or ERK. As shown in Figure 4C , apoCIII induced Ser 616 phosphorylation of IRS-1. ApoCIII-induced Ser 616 phosphorylation of IRS-1 was blocked by PKC␤-specific inhibitor and partially reversed by PD98059, an MEK1-specific inhibitor. PKC␤-specific inhibitor completely and PD98059 partially restored Tyr 989 phosphorylation of IRS-1 ( Figure 4D ). PD98059 also partially reversed the inhibitory effects of apoCIII on NO release ( Figure 4E ), suggesting the involvement of ERK in this process. In contrast, apoCIII did not activate JNK or p38 MAP kinase in endothelial cells, and apoCIII-induced Ser 616 phosphorylation of IRS-1 was not affected by their inhibitors (data not shown). Finally, we confirmed that apoCIII increased the ET-1 level in the culture media, which was abolished by PKC␤-specific inhibitor and PD98059 ( Figure  4F ). These results indicate that apoCIII may cause or augment an imbalance between vasodilator and vasoconstrictor actions of insulin through pathway-specific insulin resistance. 13, 17 
ApoCIII Inhibits Insulin Signaling in the Aortas of C57BL/6J Mice
We next tested whether apoCIII would affect an insulinstimulated eNOS pathway in vivo. Human apoCIII level in the plasma was 78Ϯ18 g/mL after 30 minutes of apoCIII (500 g per body) injection into C57BL/6J mice (mouse apoCIII level in the plasma was 38Ϯ12 and 33Ϯ14 g/mL before and after apoCIII injection, respectively). Shorttime stimulation with apoCIII did not significantly change fasting plasma triglycerides, FFA, and insulin levels (triglycerides, 52Ϯ18 and 61Ϯ19 mg/dL; FFA, 0.89Ϯ0.12 and 0.96Ϯ0.20 mmol/L; insulin, 178Ϯ18 and 167Ϯ21 pmol/L before and after 30 minutes, respectively). However, apoCIII activated PKC␤II and ERK in the aortas of C57BL/6J mice at 500 g per body ( Figure 5A and 5B). ApoCIII stimulated Ser 612 phosphorylation of IRS-1 (orthologous to Ser 616 in human IRS-1), which was attenuated by a PKC␤-specific inhibitor ( Figure 5C ). ApoCIII reduced the insulin effect on tyrosine phosphorylation of IRS-1 and eNOS in the aorta ( Figure 5D and 5E). PKC␤-specific inhibitor reversed these inhibitory effects of apo-CIII. It also restored the NO level in the plasma reduced by apoCIII ( Figure 5F ).
VLDL CIII؉ Inhibits Insulin Signaling in the Aortas of C57BL/6J Mice
ApoCIII is a component of some VLDL and other lipoproteins in blood. We tested whether VLDL CIIIϩ or VLDL CIIIϪ affects the insulin-stimulated NOS pathway in vivo. Triglycerides in VLDL CIIIϩ and VLDL CIIIϪ were 10.3Ϯ2.8 and 3.3Ϯ0.8 g/g apoB, respectively. ApoCIII in VLDL CIIIϩ was 0.80Ϯ0.14 g/g apoB. Lipid and insulin after 30 minutes of VLDL injection were as follows: triglycerides, 75Ϯ18 and 125Ϯ38 mg/dL; FFA, 1.51Ϯ0.25 and 1.63Ϯ0.35 mmol/L; and insulin, 190Ϯ34 and 184Ϯ24 pmol/L VLDL CIIIϪ and VLDL CIIIϩ, respectively. There were no significant differences in plasma FFA and insulin levels between the 2 groups. B, HUVECs were incubated with apoCIII. In experiments using PKC␤-specific inhibitor, it was added to the media at 10 nmol/L 30 minutes before apoCIII incubation. Representative blots are shown. *PϽ0.05 vs apoCIII(ϩ)/PKC␤-specific inhibitor(Ϫ). C, HUVECs were incubated with apoCIII. In experiments using PKC␤-specific inhibitor (10 nmol/L) or PD98059 (50 nmol/L), it was added to the media 30 minutes before apoCIII incubation. Representative blots are shown. *PϽ0.05 vs apoCIII(ϩ)/inhibitor(Ϫ). D, F, HUVECs were incubated with apoCIII and then stimulated with insulin (100 nmol/L for 30 minutes). In experiments using PKC␤-specific inhibitor (10 nmol/L) or PD98059 (50 nmol/L), it was added to the media 30 minutes before apoCIII incubation. Representative blots are shown. *PϽ0.05 vs apoCIII(Ϫ)/inhibitors(Ϫ); #PϽ0.05 vs apoCIII(ϩ)/inhibitors(Ϫ). E, HUVECs were incubated with apoCIII for 30 minutes and then stimulated with insulin (100 nmol/L for 30 minutes). In experiments using PD98059, it was added to the media at 50 nmol/L 30 minutes before apoCIII incubation. Representative blots are shown. p Indicates phosphorylated.
*PϽ0.01 vs apoCIII(Ϫ)/insulin(ϩ)/PD98059(Ϫ), #PϽ0.05 vs apoCIII(ϩ)/insulin(ϩ)/PD98059(Ϫ).
Human apoCIII level in plasma was 72Ϯ15 g/mL after 30 minutes of VLDL CIIIϩ injection (mouse apoCIII level in the plasma was 35Ϯ18 and 31Ϯ15 g/mL before and after VLDL CIIIϩ injection, respectively). Human VLDL CIIIϩ stimulated PKC␤II activation and Ser 612 phosphorylation of IRS-1 in the aorta of C57BL/6J mice. In contrast, VLDL CIIIϪ had minimal effect on these processes ( Figure 6A and 6B) . PKC␤-specific inhibitor partially inhibited Ser 612 phosphorylation of IRS-1 by VLDL CIIIϩ ( Figure 6C ) and restored insulin-stimulated Tyr 989 phosphorylation of IRS-1 in the aortas ( Figure 6D ) and NO release into the plasma ( Figure 6E ). VLDL CIIIϪ had minimal effect on insulin-induced NO release.
We confirmed the effect of VLDL CIIIϩ in vitro. Pretreatment of VLDL CIIIϩ with an anti-apoCIII function-blocking antibody attenuated PKC␤II activation by VLDL CIIIϩ in HUVECs (supplemental Figure IC) . VLDL CIIIϩ also is rich in apoCI and apoE (0.23Ϯ0.08 and 0.35Ϯ0.05 g/g apoB, respectively) compared with VLDL CIIIϪ. However, anti-apoCI and anti-apoE antibodies had minimal effects on PKC␤II activation (supplemental Figure IC) . Both apoCI and apoE did not activate PKC␤II of HUVECs or inhibit insulin-induced NO release into the culture media at 100 g/mL (supplemental Figure  IIA and IIB). They also did not activate PKC␤II of the aorta of C57BL/6J mice or inhibit NO release into the plasma (supplemental Figure IIC and IID) . Thus, acute administration of apoCIII-rich VLDL impaired insulin signaling in the aortas of C57BL/6J mice, suggesting the pivotal role of apoCIII itself and PKC␤II in this process. shown. *PϽ0.05 vs apoCIII(0g/mL). C, C57BL/6J mice were injected intravenously with apoCIII (500 g per body). After 30 minutes, the aortas were collected. In experiments using PKC␤-specific inhibitor, it was injected intravenously at 10 mg/kg body weight 30 minutes before apoCIII injection.
Representative blots are shown. *PϽ0.05 vs apoCIII(ϩ)/PKC␤-specific inhibitor(Ϫ). D-F, C57BL/6J mice were injected intravenously with apoCIII (500 g per body). In experiments using PKC␤-specific inhibitor, it was injected intravenously at 10 mg/kg body weight 30 minutes before apoCIII injection. After 30 minutes, animals were stimulated with intraperitoneal insulin (0.75 mU/g body weight for 10 minutes). Then, the aortas and blood were collected. Representative blots are shown. *PϽ0.05 vs apoCIII(Ϫ)/insulin(ϩ)/PKC␤-specific inhibitor(Ϫ), #PϽ0.05 vs apoCIII(ϩ)/ insulin(ϩ)/PKC␤-specific inhibitor(Ϫ).
ApoCIII Inhibits Endothelium-Dependent Relaxation in the Aortas of C57BL/6J Mice
We finally determined whether apoCIII induces endothelial dysfunction in vivo using isometric tension measurements. In preliminary experiments, carbachol-induced relaxation of the aortic ring of C57BL/6J mice was abolished by the NOS inhibitor L-N G -nitro arginine or removal of its endothelium, suggesting that the measurement reflects vascular endothelial cell-and NO-dependent relaxation (supplemental Figure III) .
ApoCIII stimulation significantly impaired endotheliumdependent relaxation of the isolated aortic rings of C57BL/6J mice, which was recovered by PKC␤-specific inhibitor ( Figure 7A ). VLDL CIIIϩ also impaired endothelium-dependent relaxation. In contrast, VLDL CIIIϪ had minimal effect on it ( Figure 7B ).
Discussion
The present study reports for the first time that apoCIII and apoCIII-rich VLDL cause insulin resistance in vascular en- Representative blots are shown. *PϽ0.05 vs VLDL CIIIϪ. C, C57BL/6J mice were injected intravenously with VLDL CIIIϩ (500 g apoB per body). After 30 minutes, the aortas were collected. In experiments using PKC␤-specific inhibitor, it was injected intravenously at 10 mg/kg body weight 30 minutes before apoCIII injection. Representative blots are shown. *PϽ0.05 vs apoCIII(ϩ)/PKC␤-specific inhibitor(Ϫ). D, E, C57BL/6J mice were injected intravenously with VLDL CIIIϩ or VLDL CIIIϪ (500 g apoB per body). In experiments using PKC␤-specific inhibitor, it was injected intravenously at 10 mg/kg body weight 30 minutes before apoCIII injection. After 30 minutes, animals were stimulated with intraperitoneal insulin (0.75 mU/g body weight for 10 minutes). Then, the aortas and blood were collected. Representative blots are shown. *PϽ0.05 vs VLDL CIIIϩ(Ϫ)/insulin(ϩ)/ PKC␤-specific inhibitor(Ϫ); #PϽ0.05 vs VLDL CIIIϩ(ϩ)/insulin(ϩ)/PKC␤-specific inhibitor(Ϫ).
dothelial cells. We provide evidence that exposure of vascular endothelial cells to apoCIII resulted in inhibition of insulinstimulated eNOS activity and NO production. Clinical studies revealed that apoCIII is associated with insulin resistance in subjects with the metabolic syndrome or type 2 diabetes. 7 It is reported that insulin resistance in hepatocytes causes apoCIII overproduction through deregulation of Foxo1. 26, 27 Our findings suggest that increased serum apoCIII is not just a clinical manifestation of insulin resistance but a causative factor for the development of insulin resistance in endothelium. Insulin action in the endothelium is mediated by the signaling pathway involving IRS-1/PI3K/Akt that leads to increased eNOS activity (the eNOS pathway). 14 PKCs play an important role in the development of insulin resistance by inhibiting this process. Naruse et al 20 reported that activation of PKC␤ in endothelial cells and vascular tissue inhibits insulin-induced Akt activation and subsequent eNOS activation. We recently showed that apoCIII in VLDL activates PKC␤ in vascular endothelial cells and induces vascular cell adhesion molecule-1 upregulation. 11 Selective inhibition of PKC␤ abolished this process. Moreover, remnant lipoproteins that are rich in apoCIII activate PKCs in human monocytic U937 cells and rat aortic smooth muscle cells. 22, 23 In the present study, apoCIII activated PKC␤II in HUVECs. ApoCIII-induced serine phosphorylation of IRS-1 was dependent on PKC␤. Indeed, a PKC␤-specific inhibitor reversed the inhibitory effect of apoCIII on this insulin signaling. Several PKC isoforms, including PKC␤II, negatively regulate IRS-1 function by serine phosphorylation. 25, 28 These results indicate a central role of PKC␤II in impaired insulin signaling induced by apoCIII. Although the mechanism(s) by which apoCIII activates PKCs in endothelial cells or monocytes remain to be fully elucidated, we recently reported that apoCIII activates PKCs through a pertussis toxin-sensitive G protein and phospholipase C in THP-1 cells, 29 suggesting that a distinct pathway or receptor may be involved in this process. Further studies are needed to elucidate the specific apoCIII signaling pathways.
This study also identified PKC␤ as the key molecule that regulates the MAP kinase and eNOS pathways. Insulin activates the small GTP binding protein Ras, which then initiates a phosphorylation cascade involving Raf, MEK, and ERK. We previously reported that apoCIII-rich remnant lipoproteins stimulate the proliferation of vascular smooth muscle cells through PKC-mediated MAP kinase activation. 23 Recent reports suggest that there is crosstalk between the eNOS and MAP kinase pathways. Andreozzi et al 24 reported that interleukin-6 impairs the vasodilator effects of insulin that are mediated by the eNOS pathway in endothelial cells through activation of JNK and ERK. These reports prompted us to examine whether apoCIII also would activate MAP kinase in HUVECs through its involvement in the eNOS pathway. We found that apoCIII itself activated ERK and augmented insulin-stimulated MAP kinase activation. The inhibition of this pathway partially reversed the effects of apoCIII on Ser 616 phosphorylation of IRS-1, suggesting that MAP kinase contributes to the impairment of the eNOS pathway. Activated MAP kinase also stimulates secretion of ET-1 from endothelial cells. In accordance, we found that apoCIII increased ET-1 release. Thus, apoCIII may cause or augment an imbalance between vasodilator and vasoconstrictor actions of insulin through its distinctive signaling pathway (Figure 8) .
We evaluated the results obtained in cultured endothelial cells in an in vivo model. Administration of apoCIII impaired insulin signaling in the aortas of C57BL/6J mice. Moreover, apoCIII impaired endothelium-dependent relaxation of aortic rings of C57BL/6J mice, suggesting that apoCIII induces endothelial dysfunction. ApoCIII-rich VLDL, but not apoCIII-deficient VLDL, exerted similar inhibitory effects, although these results reflect overall effects of apoCIII or apoCIII-rich VLDL on whole aorta, not on vascular endothelium alone. What should be noted here is that apoCIII-rich VLDL contains other apolipoproteins (eg, apoCI, E) and lipid moieties that are different from apoCIII-deficient VLDL. 5 Figure 7 . Effect of apoCIII on endothelium-dependent relaxation of the aortas of C57BL/6J mice. A, C57BL/6J mice were injected intravenously with apoCIII (500 g per body). In experiments using PKC␤-specific inhibitor, it was injected intravenously at 10 mg/kg body weight 30 minutes before apoCIII injection. After 30 minutes, the aortas were isolated for isometric tension measurements. B, C57BL/6J mice were injected intravenously with VLDL CIIIϩ or VLDL CIIIϪ (500 g apoB per body). After 30 minutes, the aortas were isolated for isometric tension measurements. PE indicates phenylephrine; CCh, carbachol. *PϽ0.05 vs VLCL CIIIϪ; #PϽ0.05 vs apoCIII.
Thus, it is possible that apoCIII may not be the only component that accounts for the effects of apoCIII-rich VLDL. Moreover, apoCIII impairs catabolism of triglyceride-rich lipoproteins in vivo, which may modify other lipid parameters that affect insulin sensitivity of endothelial cells. However, considering the results of our experiments using apoCIII alone in vitro and in vivo and those using an anti-apoCIII function blocking antibody in vitro, we conclude that apoCIII in hypertriglyceridemic VLDL directly impairs insulin signaling in vascular endothelial cells, at least in part. Previous clinical studies have shown an acute and direct effect of hypertriglyceridemia on vascular endothelium. Acute hypertriglyceridemia induced by an oral fat load caused endothelial dysfunction in subjects with dyslipidemia 30 and increased circulatory cellular adhesion molecules in healthy subjects. 31 Further study is needed to clarify the involvement of apoCIII in this phenomenon. ApoCIII impaired insulin signaling in vascular endothelial cells and caused endothelial dysfunction at Ϸ100 g/mL in vitro and in vivo. This concentration corresponds to the middle of the population range. However, it is in the upper part of the range for apoCIII in VLDL because apoCIII resides on not only apoB lipoproteins but also high-density lipoprotein. Indeed, epidemiological studies have shown a gradient of risk for apoCIII in apoB lipoproteins starting from a lower level, eg, 2 mg/dL, the first quartile. 4 Thus, we believe that apoCIII affects endothelial cells at clinically relevant concentrations in the upper part of the population distribution, supporting the clinical relevance of the present study.
Studies using apoCIII transgenic mice provide a complex, as-yet unresolved, picture of apoCIII and insulin action. Human apoCIII transgenic mice had hypertriglyceridemia and high serum FFA levels but normal glucose tolerance and normal adipocyte responses to glucose. 32, 33 Another study reported that apoCIII transgenic mice showed impaired insulin secretion, 34 which is consistent with apoCIII causing apoptosis in cultured pancreatic ␤ cells. 35 We also examined the effects of apoCIII on insulin response in other insulinsensitive cells. ApoCIII had minimal effects on insulin signaling in 3T3L1 cells and HepG2 cells (data not shown). These findings suggest that the apoCIII effect on insulin signaling may be cell-type specific.
Endothelial dysfunction associated with hypertriglyceridemia has been understood from the traditional view that FFA and other lipid moieties in triglyceride-rich lipoproteins impair insulin action and/or endothelial dysfunction. However, our findings may add a new mechanism in which triglyceride-rich lipoproteins are carriers of a causal factor for it, ie, apoCIII, although this apoCIII mechanism is not exclusive of the lipid hypothesis. Our observations provide novel insights into a role for apoCIII as a key molecule that could link dyslipidemia with endothelial dysfunction in the metabolic syndrome.
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